These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Mitomycin C in treatment of conjunctival melanoma and primary acquired melanosis].
    Author: Werschnik C, Lommatzsch PK.
    Journal: Klin Monbl Augenheilkd; 1998 Jun; 212(6):465-8. PubMed ID: 9715467.
    Abstract:
    BACKGROUND: Since 1995 we have used Mitomycin C additionally in the treatment of conjunctival melanoma and primary acquired melanosis. METHODS: We report on the therapy results of 14 patients suffering from pigmented conjunctival lesions (malignant melanoma 9 and primary acquired melanosis 5). After local excision, cryotherapy or irradiation all patients received one eye drop Mitomycin C (0.02%) four times daily for four to six weeks. RESULTS: We observed regression of the pigmentations in 11 cases after median follow up of 13.1 months. In one patient there was no change. Two cases showed progression with tumefaction. There were no adverse reactions except conjunctival hyperemia during therapy. CONCLUSIONS: Topical administration of Mitomycin C may be useful in the treatment of pigmented conjunctival lesions. Longer follow-up periods are necessary.
    [Abstract] [Full Text] [Related] [New Search]